BRISTOL-MYERS SQUIBB COMPANY Proceeds from Debt, Net of Issuance Costs
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Proceeds from Debt, Net of Issuance Costs of $5.90 billion for the 12-month period ending 2022-12-31, per its 10-K filed 2025-02-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2025-02-12
- BRISTOL-MYERS SQUIBB COMPANY proceeds from debt, net of issuance costs for fiscal 2022 was $5.90B.
- BRISTOL-MYERS SQUIBB COMPANY proceeds from debt, net of issuance costs for fiscal 2020 was $6.90B.
| Period end | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|
| 2022-12-31 | $5.90B 10-K · filed 2025-02-12 |
| 2020-12-31 | $6.90B 10-K · filed 2023-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |